All In Biotech

Free tool

FAERS Monitor: Tevimbra

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761232 or its brand name (Tevimbra, Tislelizumab-Jsgr). Reports on generic versions are filed under their own applications.

Reports

224

Serious

220

98% of reports

Hospitalization

64

Death reported

38

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • disease progression80
  • off label use26
  • malignant neoplasm progression25
  • anaemia21
  • thrombocytopenia21
  • lymphadenopathy19
  • pneumonia12
  • decreased appetite10
  • richter^s syndrome10
  • death9
  • pyrexia9
  • hyponatraemia8
  • neutrophil count decreased7
  • c-reactive protein increased6
  • infusion related reaction6

Reports by year received

View as table
YearReports
20236
202419
202572
2026127

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,935 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

FDA's data service returned an error (400). The numbers below may be missing or incomplete.
ReactionReportsPRR95% CI lowerChi-squared
disease progressionSignal8063.553.34,885
lymphadenopathySignal1950.432.8873
malignant neoplasm progressionSignal2522.915.8505
thrombocytopeniaSignal2117.611.7315
neutrophil count decreasedSignal716.17.885
c-reactive protein increasedSignal615.57.068
hyponatraemiaSignal813.36.880
anaemiaSignal2110.36.9169
infusion related reactionSignal68.53.933
decreased appetiteSignal104.02.220
pneumoniaSignal123.52.019
off label useSignal262.81.929
pyrexiaSignal92.41.36
death91.00.50
richter^s syndrome100.00.0848,266

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.